CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
Sublimity Therapeutics is developing ST-0529, an oral treatment for moderate to severe Ulcerative Colitis, utilizing their SmPill® nanoemulsion technology to deliver Cyclosporine directly to inflamed areas of the colon. This innovative approach aims to provide a safer and more effective alternative to current injectabl…
Sublimity Therapeutics has developed an innovative product, ST-0529, to treat patients with moderate-severe Ulcerative Colitis, a disease that affects 1 million patients in Europe. ST-0529 is enabled using Sublimity Therapeutics ’s proprietary SmPill® nanoemulsion-based technology to target a known and powerful drug, Cyclosporine, directly to inflamed colons.
In Phase II human studies, ST-0529 was proven to be effective and safe. ST-0529, an oral product, will compete with injected, expensive d…
SUBLIMITY THERAPEUTICS LIMITED
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
